NEPTUNUS(SZ:000078) 梧桐树下V·2025-06-08 12:39Core Viewpoint - The control change of Haiwang Biological has been terminated, ending the planned shell sale and stock issuance to specific parties due to significant financial losses and regulatory issues [1][2][4]. Group 1: Control Change and Agreements - The initial plan involved a shell sale for 767 million and a stock issuance of up to 1.488 billion [2]. - Agreements were signed in January 2024 for the transfer of shares from Haiwang Group to Silk Group, with a total of 315,734,800 shares (12% of total shares) at a price of 2.43 yuan per share [2][3]. - Following the agreements, Silk Group was set to become the controlling shareholder, holding 12% of shares and corresponding voting rights, while Haiwang Group would hold no voting rights [3]. Group 2: Financial Performance and Losses - Haiwang Biological reported a massive loss of 1.1 billion in 2024, following losses of 990 million in 2022 and 1.71 billion in 2023, marking three consecutive years of significant losses [4][5]. - The company committed to achieving a cumulative net profit of 1.2 billion over three years (2025-2027), with specific annual targets of 300 million, 400 million, and 500 million for each respective year [4]. Group 3: Regulatory Issues - The company faced regulatory scrutiny from the Shenzhen Securities Regulatory Bureau for non-compliance in information disclosure and financial accounting practices [6][7]. - Specific issues included failure to disclose external guarantees, incomplete disclosure of restricted cash, and inaccuracies in financial reporting related to guarantees and tax assets [8][9][10][11][12][13][14].